Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Höglinger GU[au]:

Search results

Items: 1 to 50 of 153

1.

Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease.

Hopfner F, Mueller SH, Szymczak S, Junge O, Tittmann L, May S, Lohmann K, Grallert H, Lieb W, Strauch K, Müller-Nurasyid M, Berger K, Schormair B, Winkelmann J, Mollenhauer B, Trenkwalder C, Maetzler W, Berg D, Kasten M, Klein C, Höglinger GU, Gasser T, Deuschl G, Franke A, Krawczak M, Dempfle A, Kuhlenbäumer G.

Mov Disord. 2020 Apr 8. doi: 10.1002/mds.28037. [Epub ahead of print]

PMID:
32267580
2.

Fibroblast Growth Factor 2-Mediated Regulation of Neuronal Exosome Release Depends on VAMP3/Cellubrevin in Hippocampal Neurons.

Kumar R, Tang Q, Müller SA, Gao P, Mahlstedt D, Zampagni S, Tan Y, Klingl A, Bötzel K, Lichtenthaler SF, Höglinger GU, Koeglsperger T.

Adv Sci (Weinh). 2020 Jan 28;7(6):1902372. doi: 10.1002/advs.201902372. eCollection 2020 Mar.

3.

Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson's Disease Patients.

Klietz M, Schnur T, Drexel S, Lange F, Tulke A, Rippena L, Paracka L, Dressler D, Höglinger GU, Wegner F.

Parkinsons Dis. 2020 Feb 24;2020:5184084. doi: 10.1155/2020/5184084. eCollection 2020.

4.

Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson's Disease.

Klietz M, Drexel SC, Schnur T, Lange F, Groh A, Paracka L, Greten S, Dressler D, Höglinger GU, Wegner F.

Brain Sci. 2020 Feb 20;10(2). pii: E111. doi: 10.3390/brainsci10020111.

5.

Consensus-Based Recommendations for Advance Directives of People with Parkinson's Disease in Regard to Typical Complications by German Movement Disorder Specialists.

Klietz M, Berndt JM, Wegner F, Schneider N, Höglinger GU, Eggers C, Stiel S.

J Clin Med. 2020 Feb 6;9(2). pii: E449. doi: 10.3390/jcm9020449.

6.

Alpha-synuclein fragments trigger distinct aggregation pathways.

Chakroun T, Evsyukov V, Nykänen NP, Höllerhage M, Schmidt A, Kamp F, Ruf VC, Wurst W, Rösler TW, Höglinger GU.

Cell Death Dis. 2020 Feb 3;11(2):84. doi: 10.1038/s41419-020-2285-7.

7.

β-adrenoreceptors and the risk of Parkinson's disease.

Hopfner F, Höglinger GU, Kuhlenbäumer G, Pottegård A, Wod M, Christensen K, Tanner CM, Deuschl G.

Lancet Neurol. 2020 Mar;19(3):247-254. doi: 10.1016/S1474-4422(19)30400-4. Epub 2020 Jan 27. Review. Erratum in: Lancet Neurol. 2020 Mar;19(3):e3. Lancet Neurol. 2020 Apr;19(4):e4.

PMID:
31999942
8.

The Progressive Supranuclear Palsy Clinical Deficits Scale.

Piot I, Schweyer K, Respondek G, Stamelou M; DescribePSP study group; ProPSP study group; MDS-endorsed PSP study group, Sckopke P, Schenk T, Goetz CG, Stebbins GT, Höglinger GU.

Mov Disord. 2020 Jan 17. doi: 10.1002/mds.27964. [Epub ahead of print]

PMID:
31951049
9.

Progressive supranuclear palsy.

Giagkou N, Höglinger GU, Stamelou M.

Int Rev Neurobiol. 2019;149:49-86. doi: 10.1016/bs.irn.2019.10.013. Epub 2019 Nov 21.

PMID:
31779824
10.

Classification of atypical parkinsonism per pathology versus phenotype.

Respondek G, Stamelou M, Höglinger GU.

Int Rev Neurobiol. 2019;149:37-47. doi: 10.1016/bs.irn.2019.10.003. Epub 2019 Nov 22.

PMID:
31779821
11.

Genetic mimics of the non-genetic atypical parkinsonian disorders - the 'atypical' atypical.

Giagkou N, Bhatia KP, Höglinger GU, Stamelou M.

Int Rev Neurobiol. 2019;149:327-351. doi: 10.1016/bs.irn.2019.10.008. Epub 2019 Nov 21.

PMID:
31779819
12.

Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons.

Ganjam GK, Bolte K, Matschke LA, Neitemeier S, Dolga AM, Höllerhage M, Höglinger GU, Adamczyk A, Decher N, Oertel WH, Culmsee C.

Cell Death Dis. 2019 Nov 14;10(11):865. doi: 10.1038/s41419-019-2091-2.

13.

Disease-modifying strategies in primary tauopathies.

Rösler TW, Costa M, Höglinger GU.

Neuropharmacology. 2020 May 1;167:107842. doi: 10.1016/j.neuropharm.2019.107842. Epub 2019 Nov 5. Review.

PMID:
31704274
14.

PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.

Schönecker S, Brendel M, Palleis C, Beyer L, Höglinger GU, Schuh E, Rauchmann BS, Sauerbeck J, Rohrer G, Sonnenfeld S, Furukawa K, Ishiki A, Okamura N, Bartenstein P, Dieterich M, Bötzel K, Danek A, Rominger A, Levin J.

Front Aging Neurosci. 2019 Sep 11;11:249. doi: 10.3389/fnagi.2019.00249. eCollection 2019.

15.

Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.

Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Roeber S, Giese A, Grossman M, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Höglinger GU; Movement Disorder Society-Endorsed Progressive Supranuclear Palsy Study Group.

Mov Disord. 2020 Jan;35(1):171-176. doi: 10.1002/mds.27872. Epub 2019 Sep 30.

PMID:
31571273
16.

Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse.

Schweyer K, Rüschoff-Steiner C, Arias-Carrión O, Oertel WH, Rösler TW, Höglinger GU.

Sci Rep. 2019 Sep 16;9(1):13359. doi: 10.1038/s41598-019-49920-5.

17.

Towards a consensus on developmental regression.

Zhang D, Bedogni F, Boterberg S, Camfield C, Camfield P, Charman T, Curfs L, Einspieler C, Esposito G, De Filippis B, Goin-Kochel RP, Höglinger GU, Holzinger D, Iosif AM, Lancioni GE, Landsberger N, Laviola G, Marco EM, Müller M, Neul JL, Nielsen-Saines K, Nordahl-Hansen A, O'Reilly MF, Ozonoff S, Poustka L, Roeyers H, Rankovic M, Sigafoos J, Tammimies K, Townend GS, Zwaigenbaum L, Zweckstetter M, Bölte S, Marschik PB.

Neurosci Biobehav Rev. 2019 Dec;107:3-5. doi: 10.1016/j.neubiorev.2019.08.014. Epub 2019 Aug 20. No abstract available.

18.

One decade ago, one decade ahead in progressive supranuclear palsy.

Stamelou M, Giagkou N, Höglinger GU.

Mov Disord. 2019 Sep;34(9):1284-1293. doi: 10.1002/mds.27788. Epub 2019 Jul 8. Review.

PMID:
31283855
19.

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.

PMID:
31278067
20.

Tau links developmental to neurodegenerative diseases.

Rösler TW, Höglinger GU.

Neurosci Biobehav Rev. 2019 Sep;104:26-27. doi: 10.1016/j.neubiorev.2019.06.015. Epub 2019 Jun 26. No abstract available.

PMID:
31254540
21.

Four-repeat tauopathies.

Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen NP, Höllerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, Müller U, Meissner WG, Kovacs GG, Höglinger GU.

Prog Neurobiol. 2019 Sep;180:101644. doi: 10.1016/j.pneurobio.2019.101644. Epub 2019 Jun 22. Review.

PMID:
31238088
22.

Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.

Hopfner F, Wod M, Höglinger GU, Blaabjerg M, Rösler TW, Kuhlenbäumer G, Christensen K, Deuschl G, Pottegård A.

Neurology. 2019 Jul 9;93(2):e135-e142. doi: 10.1212/WNL.0000000000007694. Epub 2019 May 24.

PMID:
31127070
23.

A critique of the second consensus criteria for multiple system atrophy.

Stankovic I, Quinn N, Vignatelli L, Antonini A, Berg D, Coon E, Cortelli P, Fanciulli A, Ferreira JJ, Freeman R, Halliday G, Höglinger GU, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Lang A, Levin J, Low P, Mathias C, Meissner WG, Kaufmann LN, Palma JA, Panicker JN, Pellecchia MT, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK; Movement Disorder Society Multiple System Atrophy Study Group.

Mov Disord. 2019 Jul;34(7):975-984. doi: 10.1002/mds.27701. Epub 2019 Apr 29. No abstract available.

PMID:
31034671
24.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

25.

Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Klietz M, Greten S, Wegner F, Höglinger GU.

Drugs Aging. 2019 Jun;36(6):511-530. doi: 10.1007/s40266-019-00654-z. Review.

PMID:
30937878
26.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Aug;34(8):1228-1232. doi: 10.1002/mds.27666. Epub 2019 Mar 18.

27.

Unbiased Screens for Modifiers of Alpha-Synuclein Toxicity.

Höllerhage M, Bickle M, Höglinger GU.

Curr Neurol Neurosci Rep. 2019 Feb 9;19(2):8. doi: 10.1007/s11910-019-0925-z. Review.

PMID:
30739256
28.

Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons.

Höllerhage M, Fussi N, Rösler TW, Wurst W, Behrends C, Höglinger GU.

Neuropharmacology. 2019 May 1;149:13-26. doi: 10.1016/j.neuropharm.2019.01.023. Epub 2019 Feb 4.

PMID:
30731136
29.

K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt.

Rösler TW, Salama M, Shalash AS, Khedr EM, El-Tantawy A, Fawi G, El-Motayam A, El-Seidy E, El-Sherif M, El-Gamal M, Moharram M, El-Kattan M, Abdel-Naby M, Ashour S, Müller U, Dempfle A, Kuhlenbäumer G, Höglinger GU.

Sci Rep. 2018 Nov 8;8(1):16525. doi: 10.1038/s41598-018-35003-4.

30.

Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.

Höglinger GU.

Mov Disord Clin Pract. 2018 Mar 6;5(2):141-144. doi: 10.1002/mdc3.12582. eCollection 2018 Mar-Apr.

31.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL; AL-108-231 Study Group; PROPSPERA investigators; 4RNTI-1authors; Tau Restoration on PSP (TAUROS) Investigators.

Parkinsonism Relat Disord. 2019 Mar;60:138-145. doi: 10.1016/j.parkreldis.2018.08.025. Epub 2018 Sep 4.

32.

[Tauopathies : From molecule to therapy].

Kovacs GG, Respondek G, van Eimeren T, Höller E, Levin J, Müller U, Schwarz S, Rösler TW, Schweyer K, Höglinger GU.

Nervenarzt. 2018 Oct;89(10):1083-1094. doi: 10.1007/s00115-018-0584-3. German.

PMID:
30120488
33.

New classification of tauopathies.

Höglinger GU, Respondek G, Kovacs GG.

Rev Neurol (Paris). 2018 Nov;174(9):664-668. doi: 10.1016/j.neurol.2018.07.001. Epub 2018 Aug 8. Review.

PMID:
30098799
34.

Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype.

Jabbari E, Woodside J, Tan MMX, Shoai M, Pittman A, Ferrari R, Mok KY, Zhang D, Reynolds RH, de Silva R, Grimm MJ, Respondek G, Müller U, Al-Sarraj S, Gentleman SM, Lees AJ, Warner TT, Hardy J, Revesz T, Höglinger GU, Holton JL, Ryten M, Morris HR.

Ann Neurol. 2018 Oct;84(4):485-496. doi: 10.1002/ana.25308. Epub 2018 Sep 15.

35.

Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1.

Weber A, Schwarz SC, Tost J, Trümbach D, Winter P, Busato F, Tacik P, Windhorst AC, Fagny M, Arzberger T, McLean C, van Swieten JC, Schwarz J, Vogt Weisenhorn D, Wurst W, Adhikary T, Dickson DW, Höglinger GU, Müller U.

Nat Commun. 2018 Jul 26;9(1):2929. doi: 10.1038/s41467-018-05325-y.

36.

[Current therapy studies in atypical Parkinson syndromes].

Schweyer K, Levin J, Höglinger GU.

Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S21-S29. doi: 10.1055/a-0586-3440. Epub 2018 Jul 11. Review. German.

PMID:
29996158
37.

Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy.

Fussi N, Höllerhage M, Chakroun T, Nykänen NP, Rösler TW, Koeglsperger T, Wurst W, Behrends C, Höglinger GU.

Cell Death Dis. 2018 Jul 9;9(7):757. doi: 10.1038/s41419-018-0816-2.

38.

Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges.

Respondek G, Levin J, Höglinger GU.

Curr Opin Neurol. 2018 Aug;31(4):448-454. doi: 10.1097/WCO.0000000000000581. Review.

PMID:
29746401
39.

Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up.

Schweyer K, Busche MA, Hammes J, Zwergal A, Buhmann C, van Eimeren T, Höglinger GU.

Neurology. 2018 Mar 6;90(10):482-485. doi: 10.1212/WNL.0000000000005069. No abstract available.

PMID:
29507134
40.

Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; International FTD-Genomics Consortium, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP.

PLoS Med. 2018 Jan 29;15(1):e1002504. doi: 10.1371/journal.pmed.1002504. eCollection 2018 Jan.

41.

Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, Kouri N, Ross OA, Höglinger GU, Muller U, Hardy J; International FTD-Genomics Consortium, Momeni P, Hess CP, Dillon WP, Miller ZA, Bonham LW, Rabinovici GD, Rosen HJ, Schellenberg GD, Franke A, Karlsen TH, Veldink JH, Ferrari R, Yokoyama JS, Miller BL, Andreassen OA, Dale AM, Desikan RS, Sugrue LP.

PLoS Med. 2018 Jan 9;15(1):e1002487. doi: 10.1371/journal.pmed.1002487. eCollection 2018 Jan. Erratum in: PLoS Med. 2018 Jan 29;15(1):e1002504.

42.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

43.

c.207C>G mutation in sepiapterin reductase causes autosomal dominant dopa-responsive dystonia.

Shalash AS, Rösler TW, Müller SH, Salama M, Deuschl G, Müller U, Opladen T, Petersen BS, Franke A, Hopfner F, Kuhlenbäumer G, Höglinger GU.

Neurol Genet. 2017 Nov 1;3(6):e197. doi: 10.1212/NXG.0000000000000197. eCollection 2017 Dec.

44.

Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU.

CNS Drugs. 2017 Dec;31(12):1093-1102. doi: 10.1007/s40263-017-0478-0.

PMID:
29139041
45.

Symptomatic therapy of multiple system atrophy.

Rohrer G, Höglinger GU, Levin J.

Auton Neurosci. 2018 May;211:26-30. doi: 10.1016/j.autneu.2017.10.006. Epub 2017 Oct 27. Review.

PMID:
29104019
46.

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.

Höllerhage M, Moebius C, Melms J, Chiu WH, Goebel JN, Chakroun T, Koeglsperger T, Oertel WH, Rösler TW, Bickle M, Höglinger GU.

Sci Rep. 2017 Sep 13;7(1):11469. doi: 10.1038/s41598-017-11664-5.

47.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU.

Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13. Review.

48.

Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.

Kassubek J, Huppertz HJ, Höglinger GU.

Mov Disord. 2017 Aug;32(8):1261-1262. doi: 10.1002/mds.27057. Epub 2017 Jun 7. No abstract available.

PMID:
28590575
49.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

50.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

Supplemental Content

Loading ...
Support Center